Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × MEK inhibitor I × Dermatologic × Clear all

Phase

Phase EARLY_PHASE1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1 Other solid neoplasm 1 Gastrointestinal 1 Dermatologic 1

Conditions

Interventions

Nivolumab 148 Ipilimumab 134 pembrolizumab 131 Cyclophosphamide 115 aldesleukin 63 Radiotherapy 62 fludarabine phosphate 61 Interleukin-2 61 Biopsy 48 Blood Specimen Collection 44 Temozolomide 42 fludarabine 40 Peripheral Blood Stem Cell Transplantation 40 Radiosurgery 39 trametinib 35 Vemurafenib 34 dabrafenib 30 sargramostim 29 Bevacizumab 29 Magnetic Resonance Spectroscopy 28 Aminolevulinic Acid 28 Mycophenolic Acid 26 Photochemotherapy 25 Whole-Body Irradiation 24 Surveys and Questionnaires 24 Specimen Handling 24 Imiquimod 24 Cyclosporine 23 Melphalan 22 Introns 22

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02382549 2023-12-12

Mel61

University of Virginia

Phase EARLY_PHASE1 Terminated

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡